The US FTC requires two generic drug marketing companies to divest rights and assets to two generic products as a condition for the merger (ANI Pharmaceuticals / Novitium Pharma)

FTC Requires Generic Drug Marketers ANI Pharmaceuticals, Inc. and Novitium Pharma LLC to Divest Rights and Assets to Two Generic Products as Condition of Merger* Order preserves competition in U.S. markets for generic sulfamethoxazole-trimethoprim oral suspension and generic dexamethasone The Federal Trade Commission will require generic drug marketers ANI Pharmaceuticals, Inc. and Novitium Pharma LLC to divest, to Prasco LLC, ANI’s development rights to one generic drug used to treat common infections and assets with respect to another generic drug used to treat inflammation as part of a settlement resolving charges that ANI’s $210 million

Access to this article is restricted to subscribers

Already Subscribed? Sign-in

Access to this article is restricted to subscribers.

Read one article for free

Sign-up to read this article for free and discover our services.

 

PDF Version

Author

Quotation

US Federal Trade Commission, The US FTC requires two generic drug marketing companies to divest rights and assets to two generic products as a condition for the merger (ANI Pharmaceuticals / Novitium Pharma), 10 November 2021, e-Competitions November 2021 - II, Art. N° 103576

Visites 93

All issues

  • Latest News issue 
  • All News issues
  • Latest Special issue 
  • All Special issues